Galen Center urges Malaysian government to pass tobacco control bill

Nov.29.2022
Galen Center urges Malaysian government to pass tobacco control bill
The Galen Center urges Malaysia to pass the controversial tobacco control bill within the government's first 100 days.

On November 28th, the Galen Centre for Health and Social Policy in Kuala Lumpur called on the government of Anwar Ibrahim to propose and pass the controversial tobacco control bill within the first 100 days of his tenure.


Azrul Mohd Khalib, CEO of Galen Center, has revealed that significant progress has been made on the proposed Control of Tobacco Product and Smoking Bill 2022 after undergoing several revisions suggested by the bipartisan committee of the 14th Parliament's Dewan Rakyat. The Bill proposes a ban on smoking and e-cigarette use for those born in or after 2007, also known as an intergenerational ban.


Azrul, speaking on the radio program "Health and Life: Doctors at Home" last Friday, told BFM host Tee Shiao Eek, "This is an obvious outcome because it clearly shows how different parties from different viewpoints and ideologies can collaborate to develop a multiparty bill - not even just a two-party bill - and then pass it through a vote. This has already been laid out on the table, the work has been completed.


This was an easy victory. In fact, you can submit it to parliament and vote on it at the next meeting. This is a clear example of how we can come together, work collaboratively, and create something beneficial.


In other proposed amendments, the Parliamentary Special Select Committee (PSSC) led by then-Health Minister Khairy Jamaluddin agreed to lift the ban on tobacco or electronic cigarette products for those born after January 1, 2007, but decided to maintain the ban on smoking or using e-cigarettes and purchasing such products for this group.


The 14th Parliament's PSSC has also agreed to reduce the maximum fine for GEG violators from 5,000 Malaysian Ringgit (approximately 7,923 dollars) to 500 Malaysian Ringgit (approximately 792 dollars), and may potentially offer community service.


Prior to the dissolution of parliament last month, Khairy, who was then serving in the government of Ismail Sabri Yaakob, failed to bring the tobacco bill to a second reading and debate. This was due to serious concerns raised by several Pakatan Harapan (PH) lawmakers and human rights advocates over the broad enforcement powers, economic impact, and infringement on personal liberties inherent in the bill.


Prime Minister Anwar's coalition government now holds a two-thirds majority in the Dewan Rakyat, with the addition of the Sabah branch of the United Malays National Organization (UMNO) to the coalition made up of the National Front (BN) and the Sarawak United People's Party (GPS) led by the People's Justice Party (PH).


Azrul further urges the next Health Minister to submit a Health White Paper to Parliament or release a document outlining reforms to the healthcare system for the next 15 years.


Khairy previously established a 13-member advisory committee for the "Health White Paper," co-chaired by former Health Minister Dr. S. Subramaniam and Axiata Group Chairman Shahril Ridza Ridzuan. However, there was no formation of a Health Reform Committee to oversee the implementation of recommendations outlined in the yet-to-be-released "Health White Paper.


According to Azrul, "We have put in a lot of effort, work, and contributions in considering the introduction of healthcare reform into the Malaysian healthcare system, which is stated in the white paper. Many individuals have contributed with their forward-thinking and aspirations, and most importantly, they witness the change that is needed, even earlier than the previous health minister, going back 20 years. We hope that the next minister, whoever she or he may be, will take out the white paper, present it to parliament or publicize it, so we can use the recommendations in it. It is meaningless that nobody has seen or referenced the document in this article, as it has not been made public.


In his manifesto for the 15th election, PH pledged to establish a Health Committee to oversee the implementation of the national healthcare reform plan in conjunction with the Ministry of Economic Planning, Finance, Health, and Education. The aim is to address systemic issues such as healthcare financing, decentralization of power, and the public-private partnership.


Azrul urges the PH-led coalition government not to reinvent the wheel in healthcare reform. He stated, "The proposals put forth by Kairi during his tenure stem from years of experience from those who have worked in the department. What is important for us is to recognize that regardless of who initiated these ideas in the past, we should be able to examine them and give them the attention and value they deserve. We need to do this now. If we start from scratch, we will be wasting time." Azrul suggests that the next Health Minister's first 100 days in office should focus on low-hanging fruit initiatives.


Finally, he said, "It's important to talk to people and listen to their voices. When taking office, you may have your own ideas, but I, honestly, will talk to people from the Ministry of Health, as well as other departments, and most importantly, talk to patients and patient groups. They can tell you what can be done during this time and what can be achieved.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Global tobacco leaf markets diverged sharply in 2026, with India cutting authorised FCV production amid oversupply while Malawi faced a supply shortfall. U.S. demand improved in some leaf categories, but growers in Brazil, Colombia, Tanzania and Zimbabwe faced pressure from prices, buyer access, costs and weather. With nicotine consumption patterns also shifting, 2027 will test whether supply, demand and grower profitability can move back toward balance.
Oct.26
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Russia Expands Temporary Administration of JTI Assets in Second Round: From Four to All Seven Russian Entities, With Approximately $9.5 Billion in Related Assets
Russia Expands Temporary Administration of JTI Assets in Second Round: From Four to All Seven Russian Entities, With Approximately $9.5 Billion in Related Assets
Japan Tobacco Inc. (JT) confirmed on November 9, 2026, that all seven of its Russian entities had been placed under temporary administration after a second presidential decree added three companies to the four designated a day earlier. The additional entities are associated with importing, management, holdings and the former supply of Ploom heated-tobacco devices. JT disclosed approximately ¥1.5 trillion in Russian business-related assets as of September 30, including ¥360 billion in cash and deposits, and approximately ¥200 billion in liabilities. Under its revised FY2026 forecast, Russia accounts for about 25% of adjusted operating profit. JT said operations in Russia were continuing, while the financial impact remained under assessment.
company
Nov.09
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Global PLC (NASDAQ: AIIR), a producer of flavored shisha tobacco and next-generation nicotine products, reported an 11.1% increase in third-quarter 2026 revenue to $99.8 million and a 7.7% rise in adjusted EBITDA to $30.9 million. Revenue for the first nine months increased 6.0% to $306.7 million, but the company posted a $74.2 million net loss, affected by listing-related expenses and other costs. Its New Growth Categories (NGC) business generated $2.1 million in nine-month revenue and an adjusted EBITDA loss of $10.8 million. AIR maintained its 2026 revenue growth guidance of 4%–6%, while lowering its capital expenditure outlook and raising its year-end leverage forecast from approximately 2.1 times to 2.5 times. The company has submitted a U.S. PMTA for its Crown Switch pod vape, with future contributions from new products dependent on regulatory progress and commercialization.
Capital Markets
Nov.13